- Shares of Intrexon (XON +1.4%) look to close modestly higher after the company's $26M deal for California-based Medistem (MEDS +47.7%) which develops Endometrial Regenerative Cells.
- XON says the cells "have the potential to provide treatments for conditions such as cancer, wound healing, and cardiovascular disease," when combined with integrated synthetic biology platforms.
- More specifically, XON plans to "develop two powerful classes of clinical products": Engineered stem cells for "therapeutic delivery of secreted proteins" and for "producing exosomes."
- MEDS shareholders are getting $0.27 in cash and "$1.08 worth of XON common stock." (PR)
From other sites
at CNBC.com (Dec 12, 2014)
at CNBC.com (Nov 11, 2014)
Video at CNBC.com (Nov 11, 2014)
at CNBC.com (May 14, 2014)
at CNBC.com (Mar 13, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs